Evaluation of drug targeting strategies and liposomal trafficking

被引:31
作者
Oku, N
Tokudome, Y
Asai, T
Tsukada, H
机构
[1] Univ Shizuoka, Sch Pharmaceut Sci, Dept Radiobiochem, Shizuoka 4228526, Japan
[2] Hamamatsu Photon KK, Cent Res Lab, Shizuoka, Japan
关键词
D O I
10.2174/1381612003398816
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Liposomes, that are biodegradable and essentially non-toxic, can encapsulate both hydrophilic and hydrophobic materials, and are utilized as drug carriers for drug delivery systems (DDS). Recent progress in gene technology provides a novel modality of therapy for various diseases with a variety of newly-developed cationic liposomes. Delivery of agents to the reticuloendothelial system (RES) is easily achieved since most conventional liposomes are trapped by the RES. For the purpose of delivery of agents to target organs other than RES, long-circulating liposomes have been developed by modifying the liposomal surface. Understanding of the in vivo dynamics of liposome-carried agents is required to evaluate the bioavailability of drugs encapsulated in liposomes. In this review, we focus on the in vivo trafficking of liposomes visualized by positron emission tomography (PET) and discuss the characteristics of liposomes that affect the targeting of drugs in vivo.
引用
收藏
页码:1669 / 1691
页数:23
相关论文
共 117 条
[1]   Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine [J].
Adams, LB ;
Sinha, I ;
Franzblau, SG ;
Krahenbuhl, JL ;
Mehta, RT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1638-1643
[2]   Liposomal drug formulations - Rationale for development and what we can expect for the future [J].
Allen, TM .
DRUGS, 1998, 56 (05) :747-756
[3]   LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].
ALLEN, TM ;
HANSEN, C ;
MARTIN, F ;
REDEMANN, C ;
YAUYOUNG, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36
[4]   LARGE UNILAMELLAR LIPOSOMES WITH LOW UPTAKE INTO THE RETICULOENDOTHELIAL SYSTEM [J].
ALLEN, TM ;
CHONN, A .
FEBS LETTERS, 1987, 223 (01) :42-46
[5]   THERAPY OF LEISHMANIASIS - SUPERIOR EFFICACIES OF LIPOSOME-ENCAPSULATED DRUGS [J].
ALVING, CR ;
STECK, EA ;
CHAPMAN, WL ;
WAITS, VB ;
HENDRICKS, LD ;
SWARTZ, GM ;
HANSON, WL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1978, 75 (06) :2959-2963
[6]  
[Anonymous], 1998, LONG CIRCULATING LIP
[7]  
Asai T, 1998, BIOL PHARM BULL, V21, P766
[8]   NUCLEOSIDES AND NUCLEOTIDES .122. 2'-C-CYANO-2'-DEOXY-1-BETA-D-ARABINOFURANOSYLCYTOSINE AND ITS DERIVATIVES - A NEW CLASS OF NUCLEOSIDE WITH A BROAD ANTITUMOR SPECTRUM [J].
AZUMA, A ;
NAKAJIMA, Y ;
NISHIZONO, N ;
MINAKAWA, N ;
SUZUKI, M ;
HANAOKA, K ;
KOBAYASHI, T ;
TANAKA, M ;
SASAKI, T ;
MATSUDA, A .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (26) :4183-4189
[9]   Effects of liposome-encapsulated drugs on macrophages:: comparative activity of the diamidine 4′,6-diamidino-2-phenylindole and the phenanthridinium salts ethidium bromide and propidium iodide [J].
Bakker, J ;
Sanders, A ;
Van Rooijen, N .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1998, 1373 (01) :93-100
[10]   Lipoplex-mediated gene delivery to the lung occurs within 60 minutes of intravenous administration [J].
Barron, LG ;
Gagné, L ;
Szoka, FC .
HUMAN GENE THERAPY, 1999, 10 (10) :1683-1694